CompletedPhase 2NCT01169649
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Studying Neuroendocrine neoplasm of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Diane Reidy-Lagunes, MD,MS, MD, MSMemorial Sloan Kettering Cancer Center
- Intervention
- MK-2206(drug)
- Enrollment
- 11 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2014
Study locations (1)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01169649 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm of pancreas
Additional recruiting or active studies for the same condition.